Sara Moscatelli: Apixaban in Children is Not Just Safe, But Biologically Active
Sara Moscatelli, Research Fellow at UCL, shared a post on LinkedIn about a recent article by Ghada A. Aborkhees, published in Journal of the American Heart Association, adding:
“Apixaban in children: not just safe – biologically active
We now have more than clinical outcomes.
We have mechanistic data.
What did this study actually do?
- Substudy of SAXOPHONE trial
- 182 children with heart disease
- Apixaban vs standard of care (VKA and LMWH)
- Serial hemostatic biomarkers with thrombin generation assays
Not just ‘does it work’ but how it works
Key finding
- Apixaban reduces hypercoagulability
- Decreased D-dimer
- Increased Lag time and time to peak
- Decreased Peak thrombin
- A clear shift toward less thrombin generation
But here’s the nuance (and it matters)
Apixaban does not suppress everything
Preserves endogenous thrombin potential (ETP)
No major effect on protein C and protein S
- Not a ‘blunt anticoagulant’
- More like a modulator of coagulation dynamics
Mechanistic insight
Factor Xa inhibition leads to:
- Slower thrombin initiation
- Delayed amplification
- But ongoing, controlled thrombin generation
A shift in timing, not just magnitude
The hidden variable:
- Prior VKA exposure
- Strong carryover effect at baseline
- Suppressed d-dimer and thrombin parameters
Interpretation without this leads to wrong conclusions
Clinical pearl
Transitioning from VKA to apixaban:
- Stable d-dimer levels
- No rebound hypercoagulability
- Supports safe switching strategy
What’s really important here
This is pediatric haemostasis— not adult haemostasis.
- Developmental coagulation system
- Variable protein levels
- Complex congenital heart disease physiology
And yet:
Apixaban shows predictable, consistent effects across ages
Take-home
Apixaban is not just ‘easier to use’ in children.
It produces a controlled, physiologically coherent anticoagulation profile
Not suppression.
Regulation.”
Title: Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy
Authors: Ghada A. Aborkhees, Amy J. Barr, Kevin Dietrich, Christoph Male, Zhaoqing Wang, Chen Yao, R. Mark Payne, Andrew C. Glatz, Paul Monagle, Kristin M. Burns, Alison M. Reedy, Joshua L. Dyme, Peter H. Schafer, Antoinette Ajavon-Hartmann, Lesley G. Mitchell
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 27, 2026, 14:55Diana Domenica Bruno։ Flying During Pregnancy Is Generally Safe, but Physiologic Changes Require Thoughtful Planning
-
Apr 27, 2026, 14:46Mariam Swidan: Hemolytic Anemia – Disease Overview
-
Apr 27, 2026, 14:39Talha Aman: How CABG Works to Restore Blood Flow to the Heart
-
Apr 27, 2026, 14:38Olivia Romero Lux: Raising Awareness of Bleeding Disorders in Women
-
Apr 27, 2026, 14:37Mansi Kala: Improving Patient Care in Hematological Disorders Through Diagnostic Challenges Research at ISTH 2026
-
Apr 27, 2026, 14:33Anusha Narla: Understanding Drug-Food Interaction – Levithyroxine
-
Apr 27, 2026, 14:32Juha Kotimaa։ New Insights into How APAC Shapes Complement Activation and Inflammation
-
Apr 27, 2026, 14:31Tushar Pandey: When Low Platelets Are Not ITP
-
Apr 27, 2026, 14:27Jayne Parkes: Proud to See My STP Trainee Presenting at BSH